The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 29, 2025

Filed:

Dec. 06, 2022
Applicant:

Translate Bio, Inc., Waltham, MA (US);

Inventors:

Anusha Dias, Cambridge, MA (US);

Darshan Parekh, Cambridge, MA (US);

Jeffrey S. Dubins, Cambridge, MA (US);

Christian Cobaugh, Cambridge, MA (US);

Shrirang Karve, Cambridge, MA (US);

Zarna Patel, Cambridge, MA (US);

Sara J. Dunaj, Cambridge, MA (US);

Frank Derosa, Cambridge, MA (US);

Michael Heartlein, Cambridge, MA (US);

Assignee:

TRANSLATE BIO, INC., Waltham, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/127 (2025.01); A61K 9/00 (2006.01); A61K 9/1272 (2025.01); A61K 31/7105 (2006.01); A61K 31/711 (2006.01); A61K 38/17 (2006.01); A61P 11/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/1709 (2013.01); A61K 9/0053 (2013.01); A61K 9/1272 (2013.01); A61K 31/7105 (2013.01); A61K 31/711 (2013.01); A61P 11/00 (2018.01);
Abstract

The present invention provides, among other things, methods and compositions for treating primary ciliary dyskinesia (PCD) based on mRNA therapy. The compositions used in treatment of PCD comprise an mRNA comprising a dynein axonemal heavy chain 5 (DNAH5) coding sequence and are administered at an effective dose and an administration interval such that at least one symptom or feature of PCD is reduced in intensity, severity, or frequency or has a delayed onset. mRNAs with optimized DNAH5 coding sequences are provided that can be administered without the need for modifying the nucleotides of the mRNA to achieve sustained in vivo function.


Find Patent Forward Citations

Loading…